Recently, Novo Nordisk has shared developments regarding both its insulin and GLP-1 businesses. Approximately a year ago, the company announced significant price reductions of up to 75% on several insulin products. However, several months later, Novo Nordisk decided to discontinue one of these products, the basal insulin Levemir.
While Novo Nordisk’s insulin business may not receive as much attention, the company’s GLP-1 business has been a topic of ongoing discussion. GLP-1 products, such as Ozempic and Wegovy, have gained popularity for their role in diabetes management and weight loss.
This discontinuation of Levemir is a notable development in Novo Nordisk’s insulin portfolio. It remains to be seen how this decision will impact the company’s overall insulin sales and its strategy in the diabetes market.
